Klinische Studie
Halobetasol Propionate/Tazarotene Lotion for Scalp Psoriasis: Efficacy in Itch Reduction, Disease Clearance, and Hair Appearance
Journal of Drugs in Dermatology · 2025
DOI: 10.36849/jdd.8841 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Journal of Drugs in Dermatology, 2025. Verfasst von Zoe Draelos und 1 weiteren Autor:innen. Hauptthemen laut MEDLINE: Clobetasol, Psoriasis, Nicotinic Acids, Pruritus.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
ClobetasolPsoriasisNicotinic AcidsPruritusScalp DermatosesDermatologic AgentsHairHumansMaleFemaleMiddle AgedAdultTreatment OutcomeDrug CombinationsSeverity of Illness IndexScalpSkin CreamAgedAdministration, CutaneousYoung AdultRetinoids
Substanzen
ClobetasolNicotinic AcidsDrug CombinationsDermatologic AgentstazaroteneRetinoidshalobetasol
Zitieren
APA
Draelos, Z., & Jacobson, A. (2025). Halobetasol Propionate/Tazarotene Lotion for Scalp Psoriasis: Efficacy in Itch Reduction, Disease Clearance, and Hair Appearance. Journal of Drugs in Dermatology. https://doi.org/10.36849/jdd.8841
Vancouver
Draelos Z, Jacobson A. Halobetasol Propionate/Tazarotene Lotion for Scalp Psoriasis: Efficacy in Itch Reduction, Disease Clearance, and Hair Appearance. Journal of Drugs in Dermatology. 2025. doi:10.36849/jdd.8841
BibTeX
@article{Draelos2025,
author = {Draelos, Zoe and Jacobson, Abby},
title = {Halobetasol Propionate/Tazarotene Lotion for Scalp Psoriasis: Efficacy in Itch Reduction, Disease Clearance, and Hair Appearance},
journal = {Journal of Drugs in Dermatology},
year = {2025},
doi = {10.36849/jdd.8841}
}
EUVIMED